Continuous outcomes (ie, change in core symptoms) were recorded as the mean relative changes from baseline (where possible) or mean end-point values and SD.
Among patients receiving vitamin D at baseline, the mean relative dose decreased by 22% in cinacalcet-treated patients from baseline to week 23, but was virtually unchanged (3% increase) in those receiving conventional care.
The degree of CAS correlated with neither mean relative change in rSO2 from baseline value (r = 0.327, p = 0.181) nor relative change in minimum rSO2 from baseline value (r = 0.424, p = 0.0774).
We used ANOVA modeling to test whether the mean relative change in fitness between baseline and examination year 20 differed between participants who developed incident diabetes over follow-up and those who did not.
The mean relative changes in arterial enhancement between baseline and arterial phase images showed no statistically significant differences.
Numbers needed to treat were calculated by multiplying the mean relative risk reduction with an initial mean baseline risk [ 15].
The mean relative basal contribution to total hyperglycemic exposure at baseline was 78%.
